https://www.selleckchem.com/pr....oducts/cobimetinib-g
Objective response rates were 83%, 93%, and 100%, and complete responses were 7%, 7%, and 10% in patients receiving TIRA, TIRA/IDELA, and TIRA/ENTO, respectively. As of February 21, 2019, 46/53 patients continue to receive treatment on study. CONCLUSIONS TIRA in combination with IDELA or ENTO was well tolerated in patients with CLL, establishing an acceptable safety profile for concurrent selective inhibition of BTK with either PI3Kδ or SYK. This small study did not establish a superior efficacy of the combinations o
Curtir
Comentario
Compartilhar
